Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for sarcoma.

S Fruehauf1, M R Veldwijk, S Berlinghoff

  • 1Department of Internal Medicine V, University of Heidelberg, Germany. Stefan_Fruehauf@med.uni-heidelberg.de

Cells, Tissues, Organs
|November 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working Party.

Bone marrow transplantation·2024
Same author

Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.

Bone marrow transplantation·2024
Same author

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.

Bone marrow transplantation·2023
Same author

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT.

Bone marrow transplantation·2023
Same author

Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.

Transplantation and cellular therapy·2022
Same journal

Enhancing the culture of mouse primary fibroblasts to study age-dependent effects in skin tissue engineering in vitro.

Cells, tissues, organs·2026
Same journal

Role of the Proteasome System in Shaping Cellular Immunological Characteristics and Its Impact in Modulating the Pathogenesis of Immune-Related Diseases.

Cells, tissues, organs·2026
Same journal

The Impact of Biomaterial Charge on Cells' Bioelectrical Signaling.

Cells, tissues, organs·2026
Same journal

Homer 2 regulates muscle differentiation with NFATc1.

Cells, tissues, organs·2026
Same journal

Integrating Cells, Biomaterials, and Advanced Engineering for Next-Generation Peripheral Nerve Repair.

Cells, tissues, organs·2026
Same journal

Rapid, Growth Factor-Reduced Induction of Functional Neurons from hiPSCs.

Cells, tissues, organs·2026
See all related articles

Gene therapy using the multidrug resistance 1 (MDR1) gene protected human leukocytes from chemotherapy toxicity in mice. Adeno-associated virus (AAV) vectors efficiently delivered suicide genes to sarcoma cells, offering a promising model for clinical gene therapy development.

Area of Science:

  • Oncology
  • Gene Therapy
  • Hematology

Background:

  • Soft tissue sarcomas are challenging to treat with conventional systemic therapies.
  • Increased doxorubicin dosage shows higher response rates but causes significant hematotoxicity.
  • Gene therapy offers potential solutions for both chemotherapy side effects and direct tumor targeting.

Purpose of the Study:

  • To evaluate the protective effect of multidrug resistance 1 (MDR1) gene transfer on hematopoietic stem cells against chemotherapy-induced toxicity.
  • To assess the efficacy of adeno-associated virus 2 (AAV-2) mediated suicide gene therapy against soft tissue sarcoma cells.

Main Methods:

  • Mobilized peripheral blood progenitor cells (PBPCs) were transduced with an MDR1 retroviral vector and transplanted into immune-deficient mice.

Related Experiment Videos

  • Mice received MDR1-based chemotherapy to assess leukocyte protection.
  • Human sarcoma cell lines (HS-1, HT1080) were transduced with an AAV-2 vector carrying the thymidine kinase (TK) suicide gene.
  • Transduced sarcoma cells were xenografted into NOD/SCID mice and treated with ganciclovir (GCV).

    • Main Results:

    • MDR1-transduced leukocytes showed significant protection from chemotherapy toxicity (p < 0.05).
    • Gene expression in transduced cells was 59%, higher than with less-advanced vectors.
    • AAV-2 vectors efficiently transduced sarcoma cells (>90%) with minimal transduction in PBPCs.
    • TK-transduced sarcoma cells showed complete cell kill with GCV, and mice survival exceeded 5 months post-treatment.

    Conclusions:

    • Supportive gene therapy with MDR1 can mitigate chemotherapy-induced hematotoxicity.
    • Suicide gene therapy using AAV-2 vectors is effective against soft tissue sarcomas in preclinical models.
    • Soft tissue sarcomas represent a suitable platform for developing and testing novel gene therapeutic strategies.